These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28484844)

  • 1. Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.
    Salomo K; Huebner D; Boehme MU; Herr A; Brabetz W; Heberling U; Hakenberg OW; Jahn D; Grimm MO; Steinbach D; Horstmann M; Froehner M; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1757-1769. PubMed ID: 28484844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
    Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
    Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
    Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical relevance of urine-based markers for diagnosis of bladder cancer.
    Eissa S; Swellam M; Amin A; Balbaa ME; Yacout GA; El-Zayat TM
    Med Oncol; 2011 Jun; 28(2):513-8. PubMed ID: 21437743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
    Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
    Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma.
    Srivastava R; Arora VK; Aggarwal S; Bhatia A; Singh N; Agrawal V
    Diagn Cytopathol; 2012 Sep; 40(9):755-9. PubMed ID: 22888081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
    Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
    Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.
    Li HX; Li M; Li CL; Ma JH; Wang MR; Rao J; Pan QJ
    Anal Quant Cytol Histol; 2010 Feb; 32(1):45-52. PubMed ID: 20701087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.
    Erdmann K; Salomo K; Klimova A; Heberling U; Lohse-Fischer A; Fuehrer R; Thomas C; Roeder I; Froehner M; Wirth MP; Fuessel S
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma].
    Li M; Li HX; Guo HQ; Zhao H; Zhao LL; Ma JH; Li CL; Cao J; Pan QJ
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):669-73. PubMed ID: 23159079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
    Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
    Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
    Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
    Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
    Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
    Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
    Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
    BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of urinary molecular markers in bladder cancer.
    Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
    Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH
    Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
    Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
    Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
    Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
    Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
    Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
    Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.